What the business is, and whether it's a good one at a fair price.
Operates in the pharmaceuticals and biotechnology space, reporting standalone revenue from operations of Rs 768.73 crore in FY26 against Rs 644.47 crore the year before and consolidated net profit of Rs 102.78 crore. The business carries out in-house Research and Development, with its R&D unit receiving renewal of the government's DSIR recognition in 2026. Operations extend overseas through a wholly-owned German subsidiary, Venus Pharma GmbH, which is currently undergoing restructuring with parent support pledged; the auditor has flagged Rs 28.60 crore of share application money outstanding at this subsidiary. The cost base is dominated by materials, which absorb 50.4% of revenue, while employees account for 11.5% and other operating expenses for 19.0%, leaving an EBITDA margin of 20.77% in FY26. The Board has recommended revisions to the Memorandum of Association to expand the company's stated scope into biotechnology, digital and telehealth businesses, subject to shareholder approval at the 37th AGM on August 20, 2026.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from VENUS REMEDIES LIMITED's filed financials and exchange disclosures
VENUS REMEDIES LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol VENUSREM.
Yes. Over the trailing twelve months VENUS REMEDIES LIMITED reported a net profit of ₹116 Cr on revenue of ₹811 Cr.
Not in the latest reported year — VENUS REMEDIES LIMITED's dividend payout for FY26 was nil.
Effectively yes. It holds ₹25 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, VENUS REMEDIES LIMITED ranks 53 of 169 in Pharmaceuticals — cheaper than 69% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session VENUS REMEDIES LIMITED moves 2.19% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by VENUS REMEDIES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
